|Net Assets||169.99 Mil|
|Morningstar Risk||Above Average|
|Morningstar Return||Above Average|
- Last NAV update 5/17/2013 4:00 PM ET
|The investment seeks capital appreciation. The fund invests primarily in common stocks. It normally invests at least 80% of assets in securities of companies principally engaged in the research, development, manufacture, and distribution of various biotechnological products, services, and processes, and companies that benefit significantly from scientific and technological advances in biotechnology. The fund invests in domestic and foreign issuers. It uses fundamental analysis of factors such as each issuer's financial condition and industry position, as well as market and economic conditions, to select investments. The fund is non-diversified.|
- Year to date performance as of 5/16/2013 8:00 PM ET
|Fund Family||Fidelity Investments|
|Fund Manager||Rajiv Kaul|
|Minimum Initial Purchase||2,500.00|
|Minimum IRA Investment||500.00|
- * Annualized returns
- Performance as of 5/16/2013 8:00 PM ET
|Net Assets||169.99 Mil||504.34 Mil|
|Avg Market Cap||10.40 Bil||18.61 Bil|
|NAME||% NET ASSETS|
|Gilead Sciences Inc||14.56%|
|Biogen Idec Inc||6.27%|
|Alexion Pharmaceuticals, Inc.||3.74%|
|Regeneron Pharmaceuticals, Inc.||3.58%|
|Biomarin Pharmaceutical, Inc.||2.99%|
|Onyx Pharmaceuticals, Inc.||2.63%|
Copyright © 2013 Microsoft. All rights reserved.
Quotes are real-time for NASDAQ, NYSE and AMEX. See delay times for other exchanges.
Fundamental company data and historical chart data provided by Thomson Reuters (click for restrictions). Real-time quotes provided by BATS Exchange. Real-time index quotes and delayed quotes supplied by Interactive Data Real-Time Services. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations data provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by SIX Financial Information.